CITF-funded researchers and advisors, along with federal, provincial, and territorial government health officials, gathered in Vancouver for the CITF Scientific Meeting in early March 2023. The objective was to share research results and lessons learned from three years of the COVID-19 pandemic.

Nearly 70 investigators and trainees presented original research results in the form of e-posters with explanatory videos. We have uploaded many of the posters and accompanying videos below and will add even more as research teams give us permission to share publicly. The poster presentations offer a compelling snapshot of the knowledge that has been accumulated thanks to CITF funding.

Congregate settings

Occupational and Educational cohorts

Mental health and life satisfaction among Canadian paramedics during the COVID-19 pandemic

Characterizing SARS-CoV-2 vaccine and post-infection humoral and soluble immune responses

Innate immune competence of persons with SARS-CoV-2 infection during the fifth wave in Quebec City

The impact of COVID-19 on the health of physicians, nurses and other healthcare workers: An interprovincial cohort study

Seroconversion and pseudo-neutralization in a cohort of food and retail workers in the Québec City region

Tracking COVID-19 for Safer Schools study: How robust contact tracing and serology data helped support evidence-based public health decisions and school policies for the children and youth in British Columbia during the COVID-19 pandemic

Older Canadians and long-term care residents

Descriptive analysis of post-vaccination anti-SARS-CoV-2 antibody levels among long-term care facilities residents and incidence of COVID-19

Prospective Decentralized Study Evaluating the Impact of Age on Antibody Responses to COVID-19 Vaccines in Community Dwelling Adults to 48 weeks Post Primary Vaccine Series

CMV infection in long term care residents alters global immunologic phenotype but not primary SARS-CoV-2 response

Correctional Facilities

Neutralization of Omicron Subvariants BA.5 and BQ.1 After Four COVID-19 Vaccine Doses in PLWH Receiving ART

The Serologic Prevalence of SARS-CoV-2 Amongst Incarcerated Persons in Provincial Correctional Facilities in Saskatchewan

Knowledge mobilization

Policy and decision-making

Timeliness of reporting of SARS-CoV-2 seroprevalence results and their utility for infectious disease surveillance

Accuracy of self-reported COVID-19 vaccination status compared to a public health vaccination registry

Classifying hospitalized patients testing positive for SARS-CoV-2 infection as hospitalizations primarily for COVID-19 versus hospitalizations with incidental SARS-CoV-2 infection

Community engagement

The Wellness Hub: Assessment of long-term care homes’ and retirement homes’ during the COVID-19 pandemic to inform a responsive, community of practice intervention

Co-creating implementation strategies to mitigate SARS-CoV-2 exposure risks and facilitate wellness in long-term care and retirement homes: Wellness Hub

Research recruitment and consent methods in a pandemic: A qualitative study of COVID-19 patients’ perspectives

Lessons learned: Mechanics of operating a large-scale COVID-19 immunity study in long-term care residents


COVID-19 infections and other related illnesses in the pediatric population

Factors associated with SARS-CoV-2 testing and test positivity in children and parents: A longitudinal cohort study

Waning antibody immunity against respiratory syncytial virus (RSV) during the COVID-19 pandemic and subsequent resurgence of RSV cases in young children

COVID-19 testing, vaccination and non-pharmaceutical interventions in the pediatric population

Factors associated with COVID-19 vaccination in young children: A cohort study

Parental setting of routines, limits, and child screen time during COVID-19: A cohort study

Parents’ perspectives on COVID-19 vaccinations for children: “I am not an anti-vaxxer. I am just trying to gather information and make the best decision.”

Temporal trends in adherence to non-pharmaceutical interventions among children and parents in the Greater Toronto Area

Changes in pediatric movement behaviours during the COVID-19 pandemic by stages of lockdown in Ontario, Canada: A longitudinal cohort study

Priority populations

Vaccination in high-risk patient populations

3rd and 4th doses of vaccines broaden and stabilize immunity to SARS-CoV-2 in immunocompromised patients with immune-mediated inflammatory diseases

Three doses of COVID-19 vaccines in people with HIV: Immunogenicity and effects on HIV reservoir

  • Presenter: Vitaliy Matveev

  • CITF-FUNDED PIs: Mario Ostrowski, Jennifer Gommerman, Jane Heffernan, Anne-Claude Gingras

The Vaccine Immunogenicity and Safety in ImmunoDeficient patients (VISID) study: Immunological responses of patients with primary and secondary immunodeficiencies to SARS-CoV-2 BNT162b2 and mRNA-1273 vaccines, and breakthrough infections in Canada

  • Presenter: Dana Unninayar

  • CITF-FUNDED PIs: Juthaporn Cowan, Emilia Falcone, Donald Vinh, Karina Top, Helen Decaluwe, Manish Sadarangani, Marc-André Langlois, Lisa Barrett

SARS-CoV-2 vaccine-induced T-cell response after three doses in people living with HIV on antiretroviral therapy compared to seronegative controls (CTN 328 study)  

Dynamics of cellular immune responses elicited by COVID-19 vaccines in older adults and people living with HIV receiving suppressive ART

Case management in high-risk patient populations

Frailty, age and outcomes of hospitalized adults differ across waves of the COVID-19 pandemic: A report from the Canadian Immunization Research Network (CIRN) Serious Outcomes Surveillance (SOS) Network

Vaccination during pregnancy

Impacts of the COVID-19 pandemic among 2SLGBTQQIA+ populations in Canada

SARS-CoV-2 antibody seropositivity among gay, bisexual, and other men who have sex with men (GBM) in Montreal, Toronto, and Vancouver and the role of living with HIV (LWH)

  • Presenter: Milada Dvorakova

  • CITF-FUNDED PIs: Nathan Lachowsky, Daniel Grace, Marc-André Langlois, Jesse Papenburg

Neighbourhood marginalization as a social determinant of health for SARS-CoV-2 outcomes in Canadian emergency departments

Post-COVID condition

Long COVID prevalence from Omicron BA.1/1.1: National cohort study of Canadian adults

Effect of vaccination on post-acute COVID-19 sequelae (PACS): A cross-sectional study

Evaluation of immune cell exhaustion, tolerance and metabolism in Post-Covid Condition

COVID-19 immunology

General population serosurvey

SeroTracker: Lessons learned to optimize serosurveillance platforms and methodology for COVID-19 and other respiratory viruses

Global SARS-CoV-2 seroprevalence from January 2020 to April 2022: A systematic review and meta-analysis of standardized population-based studies

Inferring the incidence of SARS-CoV-2 infection from wastewater and serological data

Immune response to SARS-CoV-2

Determining SARS-CoV-2 infection rates by nucleocapsid seropositivity in a vaccinated population with high seroprevalence

Investigation of the interplay between sex and age in antibody responses to SARS-CoV-2 infection and vaccination

Vaccine & Immunity

Vaccine Immunology

Systemic and mucosal immune responses are variably induced in response to SARS-CoV-2 mRNA vaccination in a healthy pediatric cohort

Initial spike-specific Th1-like responses to mRNA vaccination against SARS-CoV-2 correlate with the durability of serological neutralizing antibody titers

  • Presenter: Philip Samaan

  • CITF-FUNDED PIs: Mario Ostrowski, Allison McGeer, Sharon Straus, Anne-Claude Gingras

Humoral immune responses to hybrid immunity and heterologous COVID-19 vaccination: A Stop the Spread Ottawa (SSO) analysis

Intranasal immunization of HD-Ad-FS induces robust systemic and airway mucosal immunities against SARS-CoV-2 and variant infection in mice and hamsters

Profiling antibody immunity to SARS-CoV-2 vaccination

Humoral responses to bivalent vs. monovalent vaccine boosters in Canada: A Stop the Spread Ottawa (SSO) comparative analysis

Comparison of SARS-CoV-2 antibody response by demographic and clinical characteristics following natural infection and vaccination: The CANCOV study.

Vaccine safety and effectiveness

COVID-19 vaccine effectiveness by vaccine administration schedule: A CCEDRRN study

Protective effectiveness of prior SARS-CoV-2 infection and hybrid immunity against Omicron infection and severe disease: A systematic review and meta-regression

Immunogenicity and adverse events following immunization with alternate schedules of authorized COVID-19 vaccines in Canada: MOSAIC study (Mix and match of the second cOvid-19 vaccine dose for SAfety and ImmunogeniCity: a Canadian Immunization Research Network Study (CIRN)

  • Presenter: Joanne Langley

  • CITF-FUNDED PIs: Joanne Langley, Manish Sadarangani, Tania Watts, Juthaporn Cowan

Vaccine Effectiveness against Omicron hospital admission and severe outcomes: a report from the CIRN Serious Outcomes Surveillance Network

Are post-vaccination antibody levels correlated with protection against COVID after household exposure?

A multiprovincial analysis of the incidence of myocarditis or pericarditis after mRNA vaccination by varying dosing intervals, compared to the incidence after SARS-CoV-2 infection: a Canadian Immunization Research Network (CIRN) study.

What is serosurveillance and why is it important?

Serosurveillance is a common way of seeing how many people have been previously infected with a certain infectious agent, in this case SARS-CoV-2, the virus causing COVID-19. Blood samples from hundreds of thousands of Canadians are currently being tested to check levels of antibodies, which suggest a past infection. Serosurveillance can also help determine priority groups for vaccination and will be used to monitor the effectiveness of vaccines.

What does “vaccine surveillance” mean?

Vaccine surveillance includes studies of vaccine effectiveness (how good vaccines are at preventing severe disease, new infections, and transmission) and safety (identifying and quantifying the vaccine adverse effects). Although vaccines go through numerous trials before being approved for use, it is crucial to monitor their effectiveness and safety within a broader population and with various population groups (children, pregnant women, elderly, etc.).
See all FAQs